Cardivascular Risk Profile in Patients with Diabetes and Acromegaly or Cushing’s Disease – Analysis from the DPV Database

Abstract

Background Although diabetes is a common complication of acromegaly or Cushing´s disease, there are only few detailed studies with a focus on cardiovascular risk, metabolic control or diabetes therapy. Here, we provide a comprehensive characterization from the longitudinal DPV (Diabetes Patienten Verlaufsdokumentation) registry.

Methods Patients from the registry≥18 years of age with diabetes and acromegaly or Cushing´s disease were compared to patients with type 1 diabetes or type 2 diabetes using the statistical software SAS 9.4.

Results Patients with diabetes and acromegaly (n=52) or Cushing’s disease (n=15) were significantly younger at diabetes onset (median age 50.1 and 45.0 vs. 59.0 years in type 2 diabetes; both p<0.05). Dyslipidemia was common in both diseases (71.0% and 88.9% vs. 71.8% in type 2 diabetes; n.s.), while hypertension was most frequent in acromegaly (56.8% vs. 20.9% in type 1 diabetes, p<0.00001). 36.5% of patients with acromegaly and 46.7% with Cushing´s disease receive insulin, compared to 50.4% with type 2 diabetes. Oral antidiabetic drugs were used in 36.5% of patients with acromegaly and 40% with Cushing´s disease, with a predominance of biguanides and dipeptidyl peptidase-4 inhibitors. HbA1c was well controlled in both groups (median 7.0% and 6.5%; vs. 7.2% in type 2 diabetes).

Conclusion Patients with acromegaly are at a high risk for cardiovascular disease, reflected by dyslipidemia and hypertension. A high proportion of patients with diabetes in acromegaly or Cushing´s disease receives insulin. Based on a multicenter register, a sufficient number of patients with rare forms of diabetes can be analyzed.

Key words

rare diabetes - insulin - oral antidiabetic drugs - metabolic control - diabetes registry

• References

• 1 Melmed S. Medical Progress: Acromegaly. N Engl J Med. 2006; 355: 2558-2573
• 2 Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009; 30: 152-177
• 3 Fieffe S, Morange I, Petrossians P. et al. French Acromegaly Registry. Diabetes in acromegaly, prevalence, risk factors, and evolution: Data from the French Acromegaly Registry. Eur J Endocrinol. 2011; 164: 877-884
• 4 Mestron A, Webb SM, Astorga R. et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004; 151: 439-446
• 5 Dal J, Feldt-Rasmussen U, Andersen M. et al. Acromegaly incidence, prevalence, complications and long-term prognosis: A nationwide cohort study. Eur J Endocrinol. 2016; 175: 181-190
• 6 Alexopoulou O, Bex M, Kamenicky P. et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: A study in 148 patients. Pituitary 2014; 17: 81-89
• 7 Dreval AV, Trigolosova IV, Misnikova IV. et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 2014; 3: 93-98
• 8 Valassi E, Santos A, Yaneva M. et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011; 165: 383-392
• 9 Melmed S, Casanueva FF, Klibanski A. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013; 16: 294-302
• 10 Freda PU, Shen W, Heymsfield SB. et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab. 2008; 93: 2334-2343
• 11 Munir A, Newell-Price J. Management of diabetes mellitus in Cushing´s syndrome. Neuroendocrinology 2010; 92 (Suppl. 01) 82-85
• 12 Baroni MG, Giorgino F, Pezzino V. et al. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. Nutr Metab Cardiovasc Dis. 2016; 26: 85-102
• 13 Rosenbauer J, Dost A, Karges B. et al. Improved metabolic control in children and adolescents with type 1 diabetes: A trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care 2012; 35: 80-86
• 14 Schütt M, Kern W, Krause U. et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006; 114: 384-388
• 15 Taylor J. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J 2013; 34: 2108-2109
• 16 Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31: 1281-1357
• 17 American Diabetes Association, Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249
• 18 Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary 2016; 19: 536-543
• 19 Lopes AJ, Guedes da Silva DP, Ferreira Ade S. et al. What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients?. J Phys Ther Sci 2015; 27: 719-724
• 20 Cambuli VM, Galdiero M, Mastinu M. et al. Glycometabolic control in acromegalic patients with diabetes: A study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest. 2012; 35: 154-159
• 21 Bohn B, Kerner W, Seufert J. et al. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Res Clin Pract 2016; 115: 31-38